Enanta Pharmaceuticals (ENTA) AI Stock Analysis

• Market Cap: $453.43M
• Dividend Yield: N/A
• Average Volume (3M): 342.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: -3.42%
• EPS Growth: 30.03%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.87
• Shares Outstanding: 28,862,600
• 10 Day Avg. Volume: 434,456
• 30 Day Avg. Volume: 342,637
• PEG Ratio: 0.10
• Price to Book (P/B): 3.95
• Price to Sales (P/S): 3.91
• P/FCF Ratio: -7.94
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: 4.14
• Enterprise Value/Gross Profit: 4.14
• Enterprise Value/Ebitda: -3.25
• 1Y Price Target: $15.60
• Price Target Upside: -0.70% Downside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -3.04
• Revenue Forecast (FY): $65.77M

• Rating: 55 Neutral
• Price Target: $14.50 ▼(-7.70% Downside)

The overall stock score reflects significant financial challenges and valuation concerns, partially offset by positive technical indicators and promising corporate developments in RSV treatment. The financial performance remains the most critical factor, weighing heavily on the overall score.

Positive Factors

Strategic Positioning in RSV Market

Positive Phase 2b results for zelicapavir enhance Enanta's strategic position in the RSV market, potentially addressing unmet needs and driving future growth.

Innovative Drug Pipeline

Enanta's focus on HBV and NASH with innovative candidates like EDP-305 and EDP-514 highlights its commitment to addressing unmet medical needs, supporting long-term growth.

Revenue from Strategic Partnerships

Enanta's revenue model relies on strategic partnerships, providing financial stability and resources to advance its drug pipeline and sustain operations.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in maintaining market share and product demand, potentially impacting long-term financial stability and growth prospects.

Negative Cash Flow

Negative cash flows suggest operational inefficiencies and cash management challenges, limiting Enanta's ability to invest in growth and innovation.

Increased Leverage

Increased leverage raises financial risk, potentially constraining Enanta's financial flexibility and ability to navigate economic uncertainties.

Enanta Pharmaceuticals Business Overview & Revenue Model

Company Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

Enanta Pharmaceuticals generates revenue primarily through collaborations and partnerships with other pharmaceutical companies. The company engages in research and development agreements that often include upfront payments, milestone payments, and royalties on product sales. Significant partnerships, such as those with AbbVie for the development of antiviral therapies, play a crucial role in its revenue model. Additionally, Enanta may receive revenue from licensing agreements related to its drug candidates, further contributing to its overall earnings. The company's focus on advancing its pipeline and securing strategic collaborations is essential for maintaining and enhancing its revenue streams.

Enanta Pharmaceuticals Financial Statement Overview

Summary

Enanta Pharmaceuticals faces significant financial challenges, including declining revenue, negative profit margins, increased leverage, and negative cash flows. These factors indicate ongoing financial instability and operational inefficiencies.

Income Statement

Enanta Pharmaceuticals has experienced declining revenue over the past few years, with a significant drop in revenue growth rate. The company has consistently reported negative net profit margins, indicating ongoing losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Despite a slight improvement in revenue growth in the most recent year, overall profitability remains a concern.

Balance Sheet

The company's debt-to-equity ratio has increased significantly, indicating higher leverage and potential financial risk. Return on equity is negative, highlighting the company's inability to generate profit from shareholders' equity. The equity ratio has decreased, suggesting a declining proportion of equity financing. Overall, the balance sheet shows increasing financial risk and declining equity strength.

Cash Flow

Enanta Pharmaceuticals has reported negative operating and free cash flows, indicating cash outflows from operations. The free cash flow growth rate is negative, suggesting deteriorating cash generation capability. The operating cash flow to net income ratio is negative, reflecting inefficiencies in converting income into cash. Overall, the cash flow position is weak, with significant cash management challenges.

Breakdown	TTM	Dec 2025	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	64.81M	―	65.32M	67.64M	79.20M	86.16M
Gross Profit	64.81M	―	65.32M	67.64M	79.20M	86.16M
EBITDA	-82.41M	―	-70.78M	-104.51M	-123.48M	-119.22M
Net Income	-92.01M	―	-81.89M	-116.05M	-133.82M	-121.75M
Balance Sheet
Total Assets	301.03M	―	280.73M	376.65M	462.27M	380.59M
Cash, Cash Equivalents and Short-Term Investments	204.11M	―	188.86M	248.19M	369.91M	249.23M
Total Debt	207.10M	―	201.06M	226.06M	222.44M	26.69M
Total Liabilities	221.75M	―	216.01M	247.84M	245.54M	59.26M
Stockholders Equity	79.28M	―	64.72M	128.81M	216.74M	321.33M
Cash Flow
Free Cash Flow	-43.57M	―	-32.17M	-96.71M	-112.21M	-86.91M
Operating Cash Flow	-23.18M	―	-19.27M	-78.76M	-103.15M	-84.78M
Investing Cash Flow	57.12M	―	40.35M	58.23M	-53.58M	54.90M
Financing Cash Flow	-25.51M	―	-26.62M	-27.63M	198.13M	20.03M

Enanta Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENTA, the sentiment is Positive. The current price of 15.71 is above the 20-day moving average (MA) of 14.53, above the 50-day MA of 12.65, and above the 200-day MA of 8.55, indicating a bullish trend. The MACD of 0.82 indicates Negative momentum. The RSI at 66.20 is Neutral, neither overbought nor oversold. The STOCH value of 78.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENTA.

Enanta Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ENTA	55 Neutral	$453.43M	-4.09	-84.63%	―	-3.42%	30.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALLO	51 Neutral	$305.63M	-1.39	-54.43%	―	-100.00%	37.10%
ABEO	50 Neutral	$287.21M	4.55	75.90%	―	―	―
TECX	42 Neutral	$398.84M	-5.53	-32.21%	―	―	60.40%
JBIO	39 Underperform	$752.17M	-1.44	-50.23%	14.68%	―	89.16%
NMRA	33 Underperform	$292.41M	-1.20	-104.35%	―	―	20.71%

Enanta Pharmaceuticals Corporate Events

Enanta Pharmaceuticals Announces Public Stock Offering

On September 30, 2025, Enanta Pharmaceuticals announced a public offering of 6,500,000 shares of its common stock at $10.00 per share, with an option for underwriters to purchase an additional 975,000 shares. The expected net proceeds of approximately $60.6 million will support the company’s operations, with the offering set to close on October 2, 2025, subject to customary conditions.

Enanta Pharmaceuticals Announces Positive Phase 2b Results

On September 29, 2025, Enanta Pharmaceuticals announced positive topline results from its Phase 2b study of zelicapavir in high-risk adults for the treatment of respiratory syncytial virus (RSV). The study demonstrated a clinically meaningful reduction in symptom duration, supporting further development towards a Phase 3 trial. This advancement positions Enanta strategically in the RSV treatment market, potentially addressing significant unmet needs for high-risk populations, including older adults and those with chronic heart or lung diseases.

Enanta Pharmaceuticals Announces Positive Phase 2b RSV Study Results

On September 29, 2025, Enanta Pharmaceuticals announced positive topline data from its Phase 2b study of zelicapavir for treating respiratory syncytial virus (RSV) in high-risk adults. The study showed that zelicapavir, a novel N-protein inhibitor, significantly improved the time to complete resolution of RSV symptoms and demonstrated a favorable safety profile. The results suggest potential for zelicapavir as a first-in-class RSV treatment, reducing symptom duration and hospitalization rates in high-risk adults.